Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02824029
Title Ibrutinib in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Barbara Ann Karmanos Cancer Institute
Indications

Hodgkin's lymphoma

Therapies

Ibrutinib

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.